Tumor-Associated Glycolipid Antigen (TAGA) Production Service at CD BioGlyco

TAGA is a glycolipid molecule that is highly expressed on the surface of certain tumor cells or in secretions, and which is usually expressed at low or no levels in normal cells. In the past decade, significant research has been conducted on TAGAs by our team of researchers. Based on these studies and our Glyco™ Vaccine Development Platform, CD BioGlyco offers our clients thorough TAGA production service. We offer a diverse range of services, which include but are not limited to the following:

• Tumor-Associated Ganglioside Antigen Production Service

At CD BioGlyco, we are proud to offer an advanced vaccine development platform that leverages cutting-edge technologies and sophisticated research methodologies to deliver world-class tumor-associated ganglioside antigen production services. We look forward to working with you as your reliable partner. The tumor-associated ganglioside antigen production service we provide include:

• GM1 Ganglioside Antigen Production
• GD1a Ganglioside Antigen Production
• Fucosyl-GM1 Ganglioside Antigen Production
• GM2 Ganglioside Antigen Production
• GD2 Ganglioside Antigen Production
• GM3 Ganglioside Antigen Production
• GD3 Ganglioside Antigen Production
• GT3 Ganglioside Antigen Production
• 9-O-Acetyl-GD3 Ganglioside Antigen Production
• 9NHAc-GD2 Ganglioside Antigen Production

• Tumor-Associated Globo Antigen Production Service

At CD BioGlyco, we recognize the importance of innovation and staying at the forefront of scientific advancements. Our dedicated R&D team consistently explores novel approaches and methodologies to enhance our production processes of globo antigen and optimize the quality of our products. The tumor-associated globo antigen production services at CD BioGlyco are divided into the following:

• Globo-H Antigen Production
• Gb3 Antigen Production
• Gb4 Antigen Production
• Gb5 Antigen Production
• Globo-HCer Antigen Production
• MSGb5Cer Antigen Production
• DSGb5Cer Antigen Production

• Tumor-Associated Lacto-series Antigen Production Service

Our team of seasoned research and development scientists, who possess a wealth of experience, will collaborate closely with you to understand your unique needs regarding lacto-series antigen production. We place great emphasis on customization, ensuring that the services we provide are precisely aligned with your expectations. Here are the tumor-associated lacto-series antigen production services we provide:

• Le^a Antigen Production
• SLe^a Antigen Production
• Le^b Antigen Production

• Tumor-Associated Neolacto-series Antigen Production Service

With our extensive knowledge and expertise, CD BioGlyco is highly specialized in the production of tumor-associated neo-lactone series antigens. We are committed to delivering tailored solutions that cater to your specific requirements. The tumor-associated neo-lactone series antigens production service we provide include:

• Le^x Antigen Production
• SLe^x Antigen Production
• KH-1 Antigen Production
• Le^x-Le^x Antigen Production
• SLe^x-Le^x Antigen Production
• Le^y Antigen Production
• Le^y-Le^x Antigen Production

We also provide vaccine development services using TAGA as a target for vaccines. Whether for a specific tumor type or a custom design of an individualized vaccine, we are focused on providing our clients with the highest quality and innovative vaccine development services.

Applications

• By synthesizing specific glycolipid antigens, researchers can design and prepare vaccines to trigger specific immune responses.
• The synthesized glycolipid antigens can be used to study the role of these glycosylation modifications in cell biology, signaling, and disease genesis, thereby improving the understanding of the cell.
• By synthesizing specific glycolipid antigens, it is possible to study the effects of cell surface glycosylation modifications on physiological processes such as signaling, cell recognition, and adhesion.

Frequently Asked Questions

• What are the types of TAGAs?

TAGAs include a variety of glycolipid molecules, such as GM2, GD2, GD3, Globo H, and others. Each tumor may express different types of TAGAs.

• Does the TAGA apply to all types of tumors?

Not all types of tumors express TAGAs. Each type of tumor may express a different type of TAGA. Therefore, when using TAGAs for tumor-related studies, the appropriate glycolipid antigen needs to be selected on a case-by-case basis.

Fig.1 Examples of aberrantly expressed tumor-associated carbohydrate antigens on tumor surface and their associated cancers. (Jin, et al., 2017)

At CD BioGlyco, we implement robust quality control measures throughout our manufacturing facilities to ensure the reliability of our TAGA production service. In summary, CD BioGlyco is your trusted partner for glycolipid antigen manufacturing services. Please feel free to contact us if you would like more information about our services.

Reference

1. Jin, K.T.; et al. Recent advances in carbohydrate-based cancer vaccines. Biotechnology letters. 2019, 41: 641-650.